Opus Genetics Profit Margin

The latest profit margin for IRD is -2099.71% as of June 2026. That compares with 9429.06% in the prior-year period — down 122.3% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Opus Genetics's historical trend and sector peers before judging valuation or financial health.

Over the past year, IRD's profit margin moved from 9429.06% to -2099.71% — a 122.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Opus Genetics's valuation or profitability profile.

Against Healthcare companies, IRD currently prints -2099.71% for profit margin, while the sector average sits near 10.58%. That is roughly 19945.1% below the sector mean. Large gaps often invite a closer look at Opus Genetics's growth, margins, and balance sheet.

Profit Margin shows how effectively Opus Genetics converts resources into returns. At -2099.71%, IRD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 9429.06% in the prior-year period — down 122.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IRD's profit margin (-2099.71%), review year-over-year change from 9429.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.